Innovent Biologics Inc Market Cap ($17.98 Billion)
Market Cap & Net Worth: Innovent Biologics Inc (6IB)
Innovent Biologics Inc market cap. Innovent Biologics Inc (F:6IB) has a market capitalization of $17.98 Billion (€15.38 Billion) as of October 30, 2026. Listed on the F stock exchange, this Germany-based company holds position #1391 globally and #315 in its home market, demonstrating a -8.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innovent Biologics Inc's stock price €9.16 by its total outstanding shares 1740920818 (1.74 Billion).
Innovent Biologics Inc Market Cap History (2018–2026)
Innovent Biologics Inc market cap history from 2018 to 2026. Data shows growth from $4.82 Billion to $18.64 Billion (21.05% CAGR). Check today's stock price for Innovent Biologics Inc for real-time trading data and today's change.
Innovent Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innovent Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 6IB cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.32x
Innovent Biologics Inc's market cap is 1.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.14x
Innovent Biologics Inc's market cap is 21.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $4.82 Billion | $9.48 Million | -$5.77 Billion | 508.99x | N/A |
| 2019 | $5.90 Billion | $1.05 Billion | -$1.72 Billion | 5.63x | N/A |
| 2020 | $16.38 Billion | $3.84 Billion | -$998.42 Million | 4.26x | N/A |
| 2021 | $10.38 Billion | $4.27 Billion | -$3.14 Billion | 2.43x | N/A |
| 2022 | $7.82 Billion | $4.56 Billion | -$2.18 Billion | 1.72x | N/A |
| 2023 | $9.16 Billion | $6.21 Billion | -$1.03 Billion | 1.48x | N/A |
| 2024 | $8.87 Billion | $9.42 Billion | -$94.63 Million | 0.94x | N/A |
| 2025 | $17.20 Billion | $13.04 Billion | $813.57 Million | 1.32x | 21.14x |
Competitor Companies of 6IB by Market Capitalization
Companies near Innovent Biologics Inc in the global market cap rankings as of October 30, 2026. See Innovent Biologics Inc balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Innovent Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Innovent Biologics Inc (2018–2026)
Market capitalization of Innovent Biologics Inc from 2018 to today. Between 2018 and today, Innovent Biologics Inc's market cap moved from $4.82 Billion to $ 18.64 Billion, with a yearly change of 21.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €18.64 Billion | +8.36% |
| 2025 | €17.20 Billion | +93.81% |
| 2024 | €8.87 Billion | -3.11% |
| 2023 | €9.16 Billion | +17.19% |
| 2022 | €7.82 Billion | -24.71% |
| 2021 | €10.38 Billion | -36.65% |
| 2020 | €16.38 Billion | +177.59% |
| 2019 | €5.90 Billion | +22.36% |
| 2018 | €4.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Innovent Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.98 Billion USD |
| MoneyControl | $17.98 Billion USD |
| MarketWatch | $17.98 Billion USD |
| marketcap.company | $17.98 Billion USD |
| Reuters | $17.98 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, a… Read more